Treatment of bacterial inflammatory processes in adults caused by bacteria sensitive to levofloxacin: pneumonia, complicated urinary tract infections (including pyelonephritis), skin and soft tissue infections, and chronic bacterial prostatitis.
Levopro solution Storage
active substance: levofloxacin;
100 ml of solution contains levofloxacin hemihydrate in terms of anhydrous 100% levofloxacin 500 mg;
Excipients: sodium chloride, disodium edetate, dilute hydrochloric acid, sodium hydroxide, water for injections.
Levopro solution Dosage form
Solution for infusion.
Main physical and chemical properties: clear liquid from yellow to greenish-yellow color. Theoretical osmolarity – 300 mosmol / l.
Levopro solution Pharmacotherapeutic group
Antibacterial agents of the quinolone group. Fluoroquinolones.
ATX code J01M A12.
Levopro solution Pharmacological properties
Levofloxacin is a synthetic antibacterial agent from the group of fluoroquinolones, S ‑ enantiomer of a racemic mixture of the drug ofloxacin.
Mechanism of action
As an antibacterial drug from the group of fluoroquinolones, levofloxacin acts on the complex of DNA-DNA gyrase and topoisomerase IV.
Pharmacokinetic / pharmacodynamic ratio
The degree of bacterial activity of levofloxacin depends on the ratio of the maximum serum concentration (Cmax) or the area under the pharmacokinetic curve (AUC) and the minimum inhibitory (inhibitory) concentration (MIC).
Mechanism of resistance
Resistance to levofloxacin develops as a stepwise mutation of the target site in both types of topoisomerase II, DNA gyrase and topoisomerase IV. Other mechanisms of resistance, such as permeability (characteristic of Pseudomonas aeruginosa) and outflow mechanisms, may also affect sensitivity to levofloxacin.
There is cross-resistance between levofloxacin and other fluoroquinolones. Due to the mechanism of action, there is no cross-resistance between levofloxacin and other classes of antibacterial agents.
The MIC limit values for levofloxacin recommended by the European Committee for Antimicrobial Susceptibility Testing (EUCAST), which separate susceptible micro-organisms from intermediate-susceptible (moderately resistant) and intermediate-sensitive from resistant organisms, are presented in the table below.
Prescribe to adults for the treatment of infections caused by drug-sensitive microorganisms:
complicated skin and soft tissue infections
(for the above infections, the drug should be used only when the use of other antibacterial agents, which are usually recommended for the initial treatment of these infections, is impractical or impossible);
acute pyelonephritis, complicated urinary tract infections;
chronic bacterial prostatitis;
pulmonary form of anthrax: post-exposure prophylaxis and radical treatment.
Formal recommendations for the proper use of antibacterial agents should be followed.
Hypersensitivity to levofloxacin or other quinolones, epilepsy, tendon side effects after previous use of quinolones. Children’s age (up to 18 years). Pregnancy or breastfeeding.